丁苯酞联合盐酸帕罗西汀治疗缺血性脑卒中后抑郁的效果评价

Evaluation of the efficacy of butylphthalide soft capsule combined with paroxetine hydrochloride in the treatment of post-ischemic stroke depression

目的分析丁苯酞软胶囊联合盐酸帕罗西汀治疗缺血性卒中后抑郁的临床效果。方法选取2015-01—2018-01收治的150例缺血性卒中后抑郁患者,并按照随机数字法随机分为实验组和对照组,每组75例。实验组采用丁苯酞软胶囊与盐酸帕罗西汀联合治疗的方案,对照组采用盐酸帕罗西汀单独治疗方案,治疗9周后,对比观察2组患者治疗前、治疗后及组间的汉密尔顿抑郁量表(HAMD)评分、巴塞尔日常生活能力指数(MBI)评分、神经功能缺损(NIHSS)评分及不良反应发生情况。结果2组患者治疗前与治疗后的汉密尔顿抑郁量表(HAMD)评分、巴塞尔日常生活能力指数(MBI)评分、神经功能缺损(NIHSS)评分相比,差异有统计学意义(均P<0.05);2组患者治疗后的组间比较,差异有统计学意义(均P<0.01);治疗后2组均未出现不良反应。结论丁苯酞软胶囊联合盐酸帕罗西汀治疗缺血性卒中后抑郁的临床效果显著,优于单纯采用盐酸帕罗西汀治疗,且无明显不良反应。

Objective To analyze the clinical effect of butylphthalide soft capsule combined with paroxetine hydrochloride in the treatment of post ischemic stroke depression.Methods 150 patients with post ischemic post stroke depression admitted from January 2015 to January 2018 were randomly divided into experimental group and control group according to random number method,with 75 patients in each group.In the experimental group,the combination of butylphthalide soft capsule and paroxetine hydrochloride was used.The control group was treated with paroxetine hydrochloride alone.After 9 weeks of treatment,the two groups of patients were treated with Hamilton depression before,after and between groups.The scale(HAMD)score,the Basel Daily Life Ability Index(MBI)score,the neurological deficit(NIHSS)score,and the incidence of adverse reactions.Results The difference between the two groups of patients before and after treatment was the Hamilton Depression Scale(HAMD)score,the Basel Daily Living Ability Index(MBI)score,and the neurological deficit(NIHSS)score(P<0.05);There was a statistically significant difference between the two groups after treatment(P<0.01);no adverse reactions occurred in the two groups after treatment.Conclusion The clinical effect of butylphthalide soft capsule combined with paroxetine hydrochloride in the treatment of post ischemic stroke is significantly better than that of paroxetine hydrochloride alone,and no special adverse reactions.